CSPG4 and neoplasm: With the primary goal to improve the safety of CSPG4-targeting CAR T cell therapies, we used a low-affinity antibody-derived CSPG4-CAR, which showed low cytotoxic activity, consequently entailing a minimized risk for on-target/off-tumor toxicity.